Impact of a Daily Application of an Omega-3 Monoglycerides Based Serum and Cream on the Skin Microbiota
ConditionEczema
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorSCF Pharma
About this trial
This exploratory study aims to investigate the prebiotic potential of daily application of an omega-3 serum and cream to skin affected by eczema. The study will also collect data on any potential adverse effects of the products. Ten subjects will be enrolled in the study and will receive the same treatment for fourteen days. Their baseline condition before treatment will serve as a control for the effects observed after treatment on the targeted eczema area. A second area of eczema treated with the patient's usual skincare routine will also serve as a control.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Participant aged of at least 18 years old.
Participant diagnosed with eczema who did not use corticosteroids in the 14 days prior to study day 1;
Available for the entire duration of the study and willing to participate based on the information provided in the ICF duly read and signed by the latter.
Participant without intellectual problems likely to limit the validity of consent to participate in the study and compliance with protocol requirements, having the ability to cooperate adequately, understand and observe the instructions of research staff
Disqualifiers
None
Trial design
Design model
Single group
Treatments tested in this trial
Omega-3 monoglyceride based topical treatment
Other interventionSuccessive daily application of omega-3 monoglyceride based serum and cream on skin with eczema.
Treatment groups
10 Participants
are divided into 1 treatment groupGroup A: MagOX topic treatmentExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
To determine whether topical treatment with eicosapentaenoic acid monoglycerides can modulate the skin microbiota of eczema-affected skin
Quantification of the skin microbiota by quantitative Polymerase Chain Reaction (qPCR) targeting the genome of four bacteria (Staphylococcus aureus, Staphylococcus epidermis, Cutibacterium acnes and Streptococcus pyogenes) on both treated and control skin area.
Time frame
2 weeksSecondary outcomes
1
Assessment of potential adverse effects of treatment
An adverse event will be reported for any change observed by the research nurse or declared by the subject in the health of the treated skin area.
Time frame
2 weeks Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: